Debora Fumagalli1, David Venet1, Michail Ignatiadis1, Hatem A Azim1, Marion Maetens1, Françoise Rothé1, Roberto Salgado1, Ian Bradbury2, Lajos Pusztai3, Nadia Harbeck4, Henry Gomez5, Tsai-Wang Chang6, Maria Antonia Coccia-Portugal7, Serena Di Cosimo8, Evandro de Azambuja9, Lorena de la Peña10, Paolo Nuciforo11, Jan C Brase12, Jens Huober13, José Baselga14, Martine Piccart15, Sherene Loi16, Christos Sotiriou17. 1. Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium. 2. Frontier Science Scotland, Kincraig, Inverness-shire, Scotland. 3. Breast Medical Oncology Section, Yale Cancer Center, Yale School of Medicine, New Haven, Connecticut. 4. Breast Center, Department of Obstetrics and Gynecology, University of Munich, Munich, Germany. 5. Department of Medical Oncology, Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru. 6. Department of Surgery, National Cheng Kung University Hospital, Tainan, Taiwan. 7. Clinical Trial Department, Eastleigh Breast Care Centre, Pretoria, South Africa. 8. Department of Oncology, Istituto Nazionale Tumori, Milan, Italy. 9. Breast European Adjuvant Study Team, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium. 10. SOLTI-Breast Cancer Research Group, Barcelona, Spain. 11. Molecular Oncology Laboratory, Vall d'Hebron Institute of Oncology, Barcelona, Spain. 12. Novartis Pharmaceutical, Basel, Switzerland. 13. Department of Obstetrics and Gynecology, University of Ulm, Ulm, Germany. 14. Breast Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. 15. Department of Medical Oncology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium. 16. Division of Cancer Medicine and Research, Peter MacCallum Cancer Center, East Melbourne, Victoria, Australia. 17. Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium15Department of Medical Oncology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
Abstract
IMPORTANCE: In neoadjuvant trials, treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancers with dual HER2 blockade resulted in increased pathologic complete response (pCR) rates compared with each targeted agent alone. Amplification and/or overexpression of HER2 currently remains the only biomarker for therapeutic decisions, but it is insufficient to explain the heterogeneous response to anti-HER2 agents. OBJECTIVE: To investigate the ability of clinically and biologically relevant genes and gene signatures (GSs) measured by RNA sequencing to predict the efficacy of anti-HER2 agents. DESIGN, SETTING, AND PARTICIPANTS: The neoadjuvant NeoALTTO trial randomized 455 women with HER2-positive early-stage breast cancer to trastuzumab, lapatinib, or the combination for 6 weeks followed by the addition of weekly paclitaxel for 12 weeks, followed by 3 cycles of fluorouracil, epirubicin, and cyclophosphamide after surgery. The present substudy, which was planned in the NeoALTTO main protocol, evaluated the association of pretreatment gene expression levels defined using RNA sequencing with pCR and event-free survival (EFS). MAIN OUTCOMES AND MEASURES: Gene expression-based biomarkers using RNA sequencing were examined for their association with response to anti-HER2 therapy and long-term outcome. RESULTS: Sequencing data were available for 254 (56%) of the NeoALTTO participants (mean [SD] age of substudy participants, 48.8 [11.2] years). The expression of ERBB2/HER2 was the most significant predictor of pCR, followed by HER2-enriched subtype, ESR1, treatment arm, ER immunohistochemical analysis scores, Genomic Grade Index, immune, proliferation, and AKT/mTOR GSs. Adjusting for clinicopathological variables and treatment arms, ERBB2/HER2, HER2-enriched subtype, ESR1, and Genomic Grade Index remained significant. Immune GSs were associated with higher pCR only in the combination arm (odds ratio, 2.1; 95% CI, 1.2-4.0; interaction test P = .01), while the stroma GSs were significantly associated with higher pCR in the single arms and with lower pCR in the combination arm (odds ratio, 0.46; 95% CI, 0.25-0.84; P = .009). None of the evaluated variables was associated with EFS after correction for multiple testing, but this analysis was underpowered. CONCLUSIONS AND RELEVANCE: High levels of ERBB2/HER2 and low levels of ESR1 were associated with pCR in all treatment arms. In the combination arm, high expression of immune and stroma GSs were significantly associated with higher and lower pCR rates, respectively, and should be further explored as candidate predictive markers. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00553358.
IMPORTANCE: In neoadjuvant trials, treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancers with dual HER2 blockade resulted in increased pathologic complete response (pCR) rates compared with each targeted agent alone. Amplification and/or overexpression of HER2 currently remains the only biomarker for therapeutic decisions, but it is insufficient to explain the heterogeneous response to anti-HER2 agents. OBJECTIVE: To investigate the ability of clinically and biologically relevant genes and gene signatures (GSs) measured by RNA sequencing to predict the efficacy of anti-HER2 agents. DESIGN, SETTING, AND PARTICIPANTS: The neoadjuvant NeoALTTO trial randomized 455 women with HER2-positive early-stage breast cancer to trastuzumab, lapatinib, or the combination for 6 weeks followed by the addition of weekly paclitaxel for 12 weeks, followed by 3 cycles of fluorouracil, epirubicin, and cyclophosphamide after surgery. The present substudy, which was planned in the NeoALTTO main protocol, evaluated the association of pretreatment gene expression levels defined using RNA sequencing with pCR and event-free survival (EFS). MAIN OUTCOMES AND MEASURES: Gene expression-based biomarkers using RNA sequencing were examined for their association with response to anti-HER2 therapy and long-term outcome. RESULTS: Sequencing data were available for 254 (56%) of the NeoALTTO participants (mean [SD] age of substudy participants, 48.8 [11.2] years). The expression of ERBB2/HER2 was the most significant predictor of pCR, followed by HER2-enriched subtype, ESR1, treatment arm, ER immunohistochemical analysis scores, Genomic Grade Index, immune, proliferation, and AKT/mTOR GSs. Adjusting for clinicopathological variables and treatment arms, ERBB2/HER2, HER2-enriched subtype, ESR1, and Genomic Grade Index remained significant. Immune GSs were associated with higher pCR only in the combination arm (odds ratio, 2.1; 95% CI, 1.2-4.0; interaction test P = .01), while the stroma GSs were significantly associated with higher pCR in the single arms and with lower pCR in the combination arm (odds ratio, 0.46; 95% CI, 0.25-0.84; P = .009). None of the evaluated variables was associated with EFS after correction for multiple testing, but this analysis was underpowered. CONCLUSIONS AND RELEVANCE: High levels of ERBB2/HER2 and low levels of ESR1 were associated with pCR in all treatment arms. In the combination arm, high expression of immune and stroma GSs were significantly associated with higher and lower pCR rates, respectively, and should be further explored as candidate predictive markers. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00553358.
Authors: G Bianchini; L Pusztai; T Pienkowski; Y-H Im; G V Bianchi; L-M Tseng; M-C Liu; A Lluch; E Galeota; D Magazzù; J de la Haba-Rodríguez; D-Y Oh; B Poirier; J L Pedrini; V Semiglazov; P Valagussa; L Gianni Journal: Ann Oncol Date: 2015-09-19 Impact factor: 32.976
Authors: Edith A Perez; Karla V Ballman; Kathy S Tenner; E Aubrey Thompson; Sunil S Badve; Helen Bailey; Frederick L Baehner Journal: JAMA Oncol Date: 2016-01 Impact factor: 31.777
Authors: Yoichi Nagata; Keng-Hsueh Lan; Xiaoyan Zhou; Ming Tan; Francisco J Esteva; Aysegul A Sahin; Kristine S Klos; Ping Li; Brett P Monia; Nina T Nguyen; Gabriel N Hortobagyi; Mien-Chie Hung; Dihua Yu Journal: Cancer Cell Date: 2004-08 Impact factor: 31.743
Authors: Joel S Parker; Michael Mullins; Maggie C U Cheang; Samuel Leung; David Voduc; Tammi Vickery; Sherri Davies; Christiane Fauron; Xiaping He; Zhiyuan Hu; John F Quackenbush; Inge J Stijleman; Juan Palazzo; J S Marron; Andrew B Nobel; Elaine Mardis; Torsten O Nielsen; Matthew J Ellis; Charles M Perou; Philip S Bernard Journal: J Clin Oncol Date: 2009-02-09 Impact factor: 44.544
Authors: I Witzel; S Loibl; G von Minckwitz; H Eidtmann; T Fehm; F Khandan; S Schmatloch; M Hauschild; J Bischoff; P A Fasching; C Mau; C Schem; B Rack; I Meinhold-Heerlein; C Liedtke; T Karn; J Huober; C Zu Eulenburg; Y Issa-Nummer; M Untch; V Müller Journal: Br J Cancer Date: 2012-08-14 Impact factor: 7.640
Authors: Francesco Schettini; Tomás Pascual; Benedetta Conte; Nuria Chic; Fara Brasó-Maristany; Patricia Galván; Olga Martínez; Barbara Adamo; Maria Vidal; Montserrat Muñoz; Aranzazu Fernández-Martinez; Carla Rognoni; Gaia Griguolo; Valentina Guarneri; Pier Franco Conte; Mariavittoria Locci; Jan C Brase; Blanca Gonzalez-Farre; Patricia Villagrasa; Sabino De Placido; Rachel Schiff; Jamunarani Veeraraghavan; Mothaffar F Rimawi; C Kent Osborne; Sonia Pernas; Charles M Perou; Lisa A Carey; Aleix Prat Journal: Cancer Treat Rev Date: 2020-01-17 Impact factor: 12.111
Authors: Michail Ignatiadis; Gert Van den Eynden; Salgado Roberto; Marco Fornili; Yacine Bareche; Christine Desmedt; Françoise Rothé; Marion Maetens; David Venet; Esther Holgado; Virginia McNally; Astrid Kiermaier; Heidi M Savage; Timothy R Wilson; Javier Cortes; Andreas Schneeweiss; Karen Willard-Gallo; Elia Biganzoli; Christos Sotiriou Journal: J Natl Cancer Inst Date: 2019-01-01 Impact factor: 13.506
Authors: Jamunarani Veeraraghavan; Carmine De Angelis; Jorge S Reis-Filho; Tomás Pascual; Aleix Prat; Mothaffar F Rimawi; C Kent Osborne; Rachel Schiff Journal: Breast Date: 2017-07-04 Impact factor: 4.380
Authors: J Veeraraghavan; C De Angelis; R Mao; T Wang; S Herrera; A C Pavlick; A Contreras; P Nuciforo; I A Mayer; A Forero; R Nanda; M P Goetz; J C Chang; A C Wolff; I E Krop; S A W Fuqua; A Prat; S G Hilsenbeck; B Weigelt; J S Reis-Filho; C Gutierrez; C K Osborne; M F Rimawi; R Schiff Journal: Ann Oncol Date: 2019-06-01 Impact factor: 32.976
Authors: Maki Tanioka; Cheng Fan; Joel S Parker; Katherine A Hoadley; Zhiyuan Hu; Yan Li; Terry M Hyslop; Brandelyn N Pitcher; Matthew G Soloway; Patricia A Spears; Lynn N Henry; Sara Tolaney; Chau T Dang; Ian E Krop; Lyndsay N Harris; Donald A Berry; Elaine R Mardis; Eric P Winer; Clifford A Hudis; Lisa A Carey; Charles M Perou Journal: Clin Cancer Res Date: 2018-07-23 Impact factor: 12.531
Authors: Aranzazu Fernandez-Martinez; Ian E Krop; David W Hillman; Mei-Yin Polley; Joel S Parker; Lucas Huebner; Katherine A Hoadley; Jonathan Shepherd; Sara Tolaney; N Lynn Henry; Chau Dang; Lyndsay Harris; Donald Berry; Olwen Hahn; Clifford Hudis; Eric Winer; Ann Partridge; Charles M Perou; Lisa A Carey Journal: J Clin Oncol Date: 2020-10-23 Impact factor: 44.544